Hebrew University of Jerusalem
Researchers at the Hebrew University of Jerusalem discovered a method to potentially eliminate the tumor-risk factor in utilizing human embryonic stem cells, said the university on Wednesday.
The researchers’ work paves the way for further progress in the promising field of stem cell therapy, said the press release of the university sent to Xinhua.
According to the release, human embryonic stem cells are theoretically capable of differentiation to all cells of the mature human body (and are hence defined as “pluripotent“).
This ability, along with the ability to remain undifferentiated indefinitely in culture, make regenerative medicine using human
The capacity to reprogram adult patient cells into pluripotent, embryonic-like, stem cells by nuclear transfer has been reported as a breakthrough by scientists from the US and the Hebrew University of Jerusalem.
The work, described in the journal Nature, was accomplished by researchers from the New York Stem Cell Foundation Research Institute and Columbia University and by Nissim Benvenisty, the Herbert Cohn professor of Cancer Research and director of the Stem Cell Unit at the Institute of Life Sciences at the Hebrew University of Jerusalem, and his graduate student Ido Sagi. The latter assisted in the characterization of the pluripotent
Researchers at the Stanford Institute for Stem Cell Biology and Regenerative Medicine and the Sackler School of Medicine in Israel have shown how the kidneys constantly grow and have surprising ability to regenerate themselves, overturning decades of accepted wisdom that such regeneration didn’t happen. It also opens a path toward new ways of repairing and even growing kidneys.
“These are basic findings that have direct implications for kidney disease and kidney regeneration,” says Yuval Rinkevich, PhD, the lead author of the paper and a postdoctoral scholar at the institute.
The findings were published online May 15 in Cell Reports.